Prenetics Global (NASDAQ:PRE) Receives Sell (D-) Rating from Weiss Ratings

Prenetics Global (NASDAQ:PRE)‘s stock had its “sell (d-)” rating restated by stock analysts at Weiss Ratings in a research note issued to investors on Saturday,Weiss Ratings reports.

Separately, Wall Street Zen upgraded Prenetics Global to a “hold” rating in a research report on Saturday, July 5th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $9.00.

Prenetics Global Trading Down 3.6%

Shares of NASDAQ PRE opened at $16.76 on Friday. The stock has a 50 day simple moving average of $11.56 and a 200-day simple moving average of $8.71. The company has a market cap of $217.54 million, a PE ratio of -4.20 and a beta of 0.34. Prenetics Global has a 12-month low of $3.09 and a 12-month high of $17.99.

Prenetics Global (NASDAQ:PRE) last issued its quarterly earnings data on Friday, September 12th. The company reported ($0.82) earnings per share (EPS) for the quarter. The business had revenue of $17.68 million for the quarter. Prenetics Global had a negative return on equity of 31.05% and a negative net margin of 87.92%. Prenetics Global has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Prenetics Global will post -3.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Prenetics Global stock. Nomura Holdings Inc. raised its stake in Prenetics Global Limited (NASDAQ:PRE) by 3.3% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 333,528 shares of the company’s stock after buying an additional 10,576 shares during the period. Nomura Holdings Inc. owned approximately 2.73% of Prenetics Global worth $1,307,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 25.01% of the company’s stock.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.